Consequences of suboptimal glucocorticoid replacement therapy in Addison’s disease; The metabolic syndrome and QoL.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22793

Enrollment

120

Registered

2009-10-22

Start date

2010-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addison's disease, metabolic syndrome, quality of life, glucocorticoid receptor polymorphisms

Interventions

2. Measurement of blood pressure, weight, height, waist circumference

3. A fasting blood sample.

1. Questionnaires

Eligibility

Inclusion criteria

Inclusion criteria: Patients with primary adrenal insufficiency in the age of 18-70 years.

Exclusion criteria

Exclusion criteria: 1. Intercurrent infectious or serious disease; 2. Use of other oral medications containing glucocorticoids; 3. High dose inhalation glucocorticoids (>800 microgram a day); 4. Pregnancy.

Design outcomes

Primary

Measure	Time frame
1. Presence of metabolic syndrome (3 or more abnormalities of waist circumference, blood pressure, triglycerides, HDL-cholesterol, glucose); 2. Quality of life score.	—

Secondary

Measure	Time frame
Presence of glucocorticoid receptor polymorfisms in relation to the metabolic syndrome and QoL.	—

Contacts

Public ContactL.C.C.J. Smans

Department of Endocrinology; University Medical Center Utrecht, P.O. Box 85500

Smans@umcutrecht.nl+31302506304

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)